Success Story: Bringing Scientific Clarity to Biotechnology Valuation: How a Biotechnology Researcher Secured an I-140 NIW Approval
Client’s Testimonial:
"I really appreciate your team’s professional and timely help throughout the process. My unique background and proposed endeavor were very well articulated in the petition.”
On March 26th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Associate in the Field of Biotechnology (Approval Notice).
General Field: Biotechnology
Position at the Time of Case Filing: Senior Associate
Country of Origin: China
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: March 26th, 2026
Processing Time: 1 month, 20 days (Premium Processing Upgrade Requested)
Case Summary:
Our client, holding a Ph.D. in Immunology & Microbial Pathogenesis, works in the field of biotechnology at the intersection of biomedical science, translational analysis, and biotechnology finance. In this I-140 NIW case, we presented the client’s proposed endeavor as continuing research on qualitatively and quantitatively analyzing publicly available pre-clinical and clinical data of investigational therapies and financial statements of biotech companies in order to help investors and the public appreciate fair drug and company value, promote market efficiency, and assist companies in securing capital for development efforts. We argued that this work has clear substantial merit and national importance because better science-driven valuation can improve capital allocation, strengthen market transparency, and help promising therapies reach development milestones more efficiently. At the time of filing, the client was employed in biotech equity research, and the petition showed that this ongoing work was directly aligned with the proposed endeavor.
The Foundation: A Strong Record of Research and Peer Recognition
To show that the client was well-positioned to advance the endeavor, we did not rely on the client’s metrics as bare numbers. Instead, we framed them as objective signs of recognized expertise and independent reliance. The petition highlighted a scholarly record that included:
- 7 peer-reviewed journal articles, including 1 first-authored
- 247 citations
- At least 16 completed peer reviews
We explained why these metrics mattered. A publication record of this kind shows sustained research activity in complex biomedical subjects rather than isolated participation. The peer review record indicates that journals viewed the client as qualified to evaluate the work of other researchers, which is a meaningful signal of professional trust. The citation record was also interpreted in context.
The petition also connected the client’s significance to the substance of the underlying research. We highlighted work involving inflammatory disease mechanisms, cancer-related pathways, immune regulation, and translational biomedical analysis. This mattered strategically because it showed that the client’s current biotechnology valuation research was grounded in real scientific expertise.
The Endorsement: Validation from Experts in the Field
The case also included 3 recommendation letters to reinforce that the client’s record and proposed endeavor carried significance beyond a single role or employer. These letters supported the argument that the client’s background in biotechnology, translational medicine, and scientific analysis positioned him to continue producing work with broader value to the United States.
"Taken together, [Client’s] accomplishments mark him as an invaluable asset to the United States who is impacting both theoretical understanding and practical applications in his field."
We also showed that the client’s work had been supported by major funding sources, including the National Institutes of Health and the American Cancer Society. In the petition, that funding was not presented as prestige alone. Instead, it was used as objective evidence that the client’s prior research addressed problems that funding bodies viewed as important to public health and scientific advancement. This helped strengthen the broader argument that the client’s expertise was already being applied in areas of recognized national value.
By integrating the client’s advanced training, publication record, citation history, peer review service, recommendation letters, and funding support into a coherent Dhanasar analysis, we demonstrated both the national importance of the proposed endeavor and that the client was well-positioned to carry it forward.
We are delighted that this I-140 NIW petition was approved and look forward to the client’s continued contributions to biotechnology, market efficiency, and the advancement of science-driven healthcare innovation.